NAD+ / MOTS-c / 5-Amino-1MQ

Overview

NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. NAD+ support targets redox and energy pools, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism. [2][4][5][9]

The biochemical rationale is coherent, but this is not a validated human longevity protocol. NAD+ precursors, MOTS-c, and 5-Amino-1MQ sit at very different evidence levels. [3][6][10]

Peptides in this stack

Why They're Combined

The stack is built around energy metabolism from three angles. NAD+ precursors support the NAD+ pool, MOTS-c is a mitochondrial-derived peptide linked with metabolic stress signaling, and 5-Amino-1MQ is discussed as an NNMT inhibitor that may affect nicotinamide handling and adipose metabolism. [2][4][5][8][9]

The practical idea is not one longevity lever. It is a base layer for NAD+ availability, a mitochondrial signaling layer, and a metabolic-enzyme layer. That makes the stack conceptually organized, but still highly dependent on each component's evidence quality. [2][7][10]

How They Work Together

The proposed mechanism starts with NAD+ as a cellular cofactor for redox and signaling biology. MOTS-c adds a mitochondrial stress-response and exercise-linked signaling rationale, while 5-Amino-1MQ targets NNMT, an enzyme connected to nicotinamide metabolism and adipose energy handling. [2][5][7][8]

In plain terms, the stack tries to connect energy availability, mitochondrial adaptation, and metabolic enzyme signaling. That makes it conceptually tighter than a loose longevity mix, but the mechanism still has to survive real human testing as a combination. [3][6][10]

What the Evidence Shows

NAD+ precursors have the most direct human supplement literature in this stack. MOTS-c has human biomarker and exercise-context literature plus substantial mechanistic work. 5-Amino-1MQ remains much more preclinical, with animal and NNMT-target literature doing most of the work. [1][3][6][4][9][10]

No controlled human trial establishes this three-part stack for longevity, fat loss, insulin sensitivity, mitochondrial function, or exercise performance. The combination should be treated as a mechanistic stack with uneven evidence, not a validated metabolic protocol. [2][6][10]

Typical Protocol

Common NAD+ precursor schedules use NMN or NR at 250-1000 mg daily, usually in the morning. Common MOTS-c injectable protocols use 5-10 mg per dose, often morning or pre-workout. Common 5-Amino-1MQ oral protocols use 50-100 mg once daily, usually in the morning. [3][2][4][9]

A clean metabolic stack keeps NAD+ support and 5-Amino-1MQ daily, places MOTS-c on fixed injection days, and uses an 8-12 week reassessment window. Weight, waist, fasting glucose, exercise capacity, sleep, appetite, and GI tolerance are the practical tracking points. [2][7][10]

Important Considerations

The evidence is uneven across the three components. NAD+ precursors have the most human data, MOTS-c is much less translated, and 5-Amino-1MQ is still highly experimental. Oral NAD+ precursors are also not interchangeable with injectable NAD+ clinic protocols, so route, form, and evidence level need to stay separate. [2][1]

The stack can become noisy quickly because diet, training, sleep, fasting, glucose status, and body weight all affect the same outcomes. Product identity and stability matter for all three components, and glucose-lowering medications or aggressive calorie restriction can change the risk profile. Change one variable at a time if the goal is to learn anything from the protocol. [3][6][10]

Published research 10 sources